Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.280 +0.0% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4% S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.280 +0.0% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4%
M&A / Property

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

By The Northwire Desk — AI Analysis Nov 20, 2025 · 06:42 NTLX · 0.165 NeuroThera Labs Inc.
NTLX · Price

Executive Summary

  • SciSparc Ltd., which holds a ~75% controlling interest in NeuroThera Labs Inc., announced the filing of an Israeli patent application for a novel combination therapy (MEAI + N‑Acylethanolamines such as PEA) targeting depression, developed with Clearmind Medicine Inc.
  • The filing expands the joint IP portfolio to 13 patents covering MEAI/PEA combinations for multiple CNS and addiction indications (alcohol use disorder, cocaine addiction, obesity/weight loss, and depression).
  • The announcement underscores SciSparc’s strategic focus on cannabinoid‑based therapeutics and its effort to build a robust pipeline of CNS treatments.

Key Details

  • Patent Filing: Israeli patent application for the combination therapy of 5‑methoxy‑2‑aminoindane (MEAI) and N‑Acylethanolamines (e.g., Palmitoylethanolamide, PEA).
  • Collaboration Partner: Clearmind Medicine Inc. (Nasdaq: CMND).
  • Therapeutic Target: Depression; the same platform is being explored for alcohol use disorder, cocaine addiction, obesity/weight loss, and other CNS disorders.
  • Ownership Structure: SciSparc holds approximately 75% of NeuroThera Labs Inc., the entity filing the patent.
  • IP Portfolio Size: 13 patents filed to date under the SciSparc‑NeuroThera‑Clearmind collaboration.
  • Preclinical Support: Data indicate MEAI’s efficacy in reducing addictive behaviors while preserving normal reward pathways.
  • Market Context: WHO data (Aug 2025) cite ~332 million people living with major depressive disorder worldwide (~5.7% of adults).

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from NeuroThera Labs Inc.

Jun 30, 2026 · 18:00

Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.

Financings Jun 03, 2026 · 17:15

Neurothera Closes Cashless Quantum-Tech Acquisition, But Dilution and Clinical Stage Risks Keep Upside Capped

M&A / Property May 27, 2026 · 08:00

Neurothera Labs Confirms Acquisition Closing Amidst Significant Equity Dilution and Regulatory Scrutiny

M&A / Property Mar 16, 2026 · 07:31

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

M&A / Property Mar 11, 2026 · 07:30

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Other Mar 10, 2026 · 07:30

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

M&A / Property